C-Reactive Protein Testing Market Report 2025

The c-reactive protein testing market size has grown steadily in recent years. It will grow from $3.45 billion in 2024 to $3.55 billion in 2025 at a compound annual growth rate (CAGR) of 2.9%. The growth in the historic period can be attributed to increased inflammatory disease prevalence, cardiovascular risk assessment, increased aging population, increased healthcare infrastructure, and healthcare screening programs.

The c-reactive protein testing market size is expected to see strong growth in the next few years. It will grow to $4.35 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to rising obesity rates, personalized medicine and biomarkers, telehealth and remote monitoring, early disease detection, and lifestyle-related inflammation. Major trends in the forecast period include diagnostic testing advancements, wearable health technology, technological solutions, strategic collaborations, and industry 4 introduction.

The rise in cardiovascular disease (CVD) cases is expected to drive the growth of the C-reactive protein testing market. Cardiovascular diseases encompass heart conditions such as diseased vessels, structural issues, and blood clots. While the exact cause of CVD is not fully understood, several factors can increase the risk of developing it. One significant factor is behavioral risk, stemming from poor diet, insufficient physical activity, smoking, and alcohol consumption, which leads to the buildup of fatty deposits in the arteries (atherosclerosis) and heightens the risk of blood clots. These behavioral risks contribute to elevated blood pressure, glucose levels, blood lipids, weight gain, and obesity. As CVD cases rise, there is an increasing demand for C-reactive protein testing to diagnose or predict the likelihood of cardiovascular issues, similar to cholesterol testing. For example, in December 2023, the Institute for Health Metrics and Evaluation reported that global deaths from cardiovascular diseases reached 19.8 million in 2022, with ischemic heart disease accounting for 108.8 deaths per 100,000 people. High systolic blood pressure was the leading contributor to disability-adjusted life years (DALYs) associated with CVD, while dietary risks and air pollution emerged as significant behavioral and environmental factors exacerbating this global issue.

The increasing number of clinical trials is anticipated to further boost the c-reactive protein testing market. Clinical trials play a crucial role in assessing the safety, efficacy, and potential benefits of medical interventions, including diagnostic procedures like c-reactive protein testing. These trials are instrumental in evaluating the accuracy and efficacy of CRP testing in diagnosing cardiovascular diseases and predicting the risk of heart-related conditions. As of May 2023, there are 452,604 clinical studies registered on ClinicalTrials.gov, with 64,838 actively seeking participants, marking a notable increase from early 2021. This rise in clinical trials underscores the growing importance of c-reactive protein testing, contributing to the market's expansion.

A noteworthy trend in the c-reactive protein testing market is the technological advancement in measuring devices. Key players in the market are prioritizing technological innovation to strengthen their market positions. These companies are integrating next-generation c-reactive testing technologies into their methods, providing advanced solutions with benefits like maximum output and multiple usages. For example, Aidian, a Finnish-based diagnostic tests and solutions company, introduced the QuikRead go wrCRP & wrCRP+Hb kits in February 2022. This kit delivers two results, a wide range of CRP and Hb, from a single sample with one analysis. The wide-range CRP test allows for CRP readings that assess conditions like neonatal sepsis, predict disease severity in COPD, and aid in cardiovascular risk assessment. This technological advancement reflects a commitment to offering efficient and comprehensive c-reactive protein testing solutions.

Key players in the c-reactive protein testing market are prioritizing innovation by introducing new technological treatments, such as the C-Reactive Protein antigen test, to enhance their market standing and profitability. The C-Reactive Protein (CRP) antigen test is a blood test designed to measure the body's level of C-Reactive Protein, a protein produced by the liver in response to inflammation. LumiraDx Healthcare Pvt Ltd., an India-based medical technology company, launched the C-Reactive Protein antigen test in November 2022. This microfluidic immunoassay offers a quick and simple way to measure CRP levels in whole blood, providing an automated in vitro diagnostic test for healthcare professionals to use in close proximity to patients.

In June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired ReViral Ltd. for $525 million. This acquisition enhances Pfizer's anti-infective portfolio and reinforces its commitment to developing medicines and vaccines to combat respiratory syncytial virus (RSV). ReViral Ltd. is a UK-based biotech company that specializes in innovative therapies for viral diseases and C-reactive protein (CRP) testing.

Major companies operating in the c-reactive protein testing market include Thermo Fisher Scientific Inc., F Hoffmann-La Roche AG, Danaher Corporation, Quest Diagnostics Incorporated, Siemens AG, Abbott Laboratories, Aidian Oy, Boditech Med Inc., Horiba Ltd., Laboratory Corporation, Merck KGAA, Randox Laboratories Limited, Getein Biotech Inc., Bio-Rad Laboratories Inc., DiaSorin S.p.A., Eurofins Scientific SE, Inova Diagnostics Inc., Luminex Corporation, Sekisui Diagnostics LLC, Sysmex Corporation, Tosoh Corporation, Trinity Biotech Plc, WerfenLife Group LLC, ZEUS Scientific Inc., BioMérieux SA, Biomerica Inc., Gold Standard Diagnostics Corp., Immunodiagnostic Systems Holdings PLC, Nova Biomedical Corporation.

C-reactive protein (CRP) testing is a diagnostic procedure that assesses the concentration of CRP in the bloodstream, a protein produced by the liver in response to inflammation. In cases of injury or infection, the body initiates inflammation as a protective mechanism. CRP testing is primarily employed to identify inflammation resulting from infections.

The primary assay methods utilized in the CRP testing market include enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), and immunoturbidimetric assays. ELISA, for instance, is a technique employed to quantitatively measure human CRP levels in serum, aiding in the monitoring of conditions such as rheumatic fever and inflammatory processes. ELISA serves as a biological assay focusing on the measurement of antibodies, antigens, proteins, and glycoproteins. CRP testing is widely applied in clinical settings, hospitals, and diagnostic laboratories, contributing to the diagnosis and monitoring of various conditions such as diabetes, rheumatoid arthritis, cardiovascular diseases, inflammatory bowel disease, cancer, and others.

The c-reactive protein testing market research report is one of a series of new reports that provides c-reactive protein testing market statistics, including c-reactive protein testing industry global market size, regional shares, competitors with an c-reactive protein testing market share, detailed c-reactive protein testing market segments, market trends and opportunities, and any further data you may need to thrive in the c-reactive protein testing industry. This c-reactive protein testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the c-reactive protein testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the c-reactive protein testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the c-reactive protein testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The c-reactive protein testing market includes revenues earned by entities by devices and reagents. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.